Answers are grounded in this paper and cite their sources.
Background Respiratory viruses including human parainfluenza virus (hPIV), respiratory syncytial virus (RSV), and human metapneumovirus (hMPV), pose serious, potentially lethal threats to humans, particularly infants and young children. While maternal vaccines and monoclonal antibodies are advancing to provide transient protection against these viruses, licensed pediatric vaccines are not yet available. Sendai virus (SeV) is now being developed as an intranasal (I.N.) vaccine candidate for the prevention of serious respiratory viral infections in children. Methods To examine the potential of replication-competent Sendai virus and its recombinants as pediatric respiratory virus vaccines against hPIV, RSV and hMPV, we searched literature databases and evaluated both historical and contemporary published research. Results SeV and SeV recombinant vaccines have been tested pre-clinically in a variety of animal models and in Phase I clinical studies. In pre-clinical models, a single dose of SeV induced rapid and long-lasting B- and T-cell responses in the upper respiratory tract and blood. When recombinant SeV constructs were produced and formulated into cocktail vaccines, they were protective against four different respiratory pathogens simultaneously. Vaccines were successful when partnered with passively transferred antibodies; specifically, when a recombinant SeV-based RSV vaccine was tested in the presence of passively transferred monoclonal or polyclonal PIV-specific or RSV-specific antibodies in a cotton rat model, the vaccine provided durable protective immunity against RSV. In clinical trials, SeV was well-tolerated and uniformly immunogenic in PIV-seropositive 1–2 year old children. Methods have been developed for the manufacture of stable SeV-based vaccine products, compatible with wide global distribution of SeV vaccines for clinical use. Conclusion To date, results highlight SeV as an attractive pediatric vaccine candidate. Continued clinical testing of SeV may provide global relief from serious respiratory viral infections in infants and young children.
No takes yet. Share an insight, caveat, or question.
Jones et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: